National Institutes of Health
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, closing November 5, 2027.
Overview
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.…